Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 49

  • 956 clinical trials
  • 393 recruiting
  • 345 conditions
  • 28 countries

Conditions in this area

345 conditions with trials, the busiest first

Breast cancer168Prostate cancer101Ovarian cancer91Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer41Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer18Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+321

Clinical trials in Reproductive system and breast disorders

956 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

956 clinical trials

Breast cancer+1

Not recruiting

Study of PF-07220060 and Letrozole for Adults with HR-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Pfizer Inc.

Endometrial cancer+4

Not recruiting

Study on Raludotatug Deruxtecan for Patients with Advanced or Metastatic Solid Tumors, Including Gynecological and Genitourinary Cancers

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Raludotatug Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Prostate cancer

Not recruiting

Study on the Safety and Feasibility of PSMA-T4 for Prostate Cancer Patients

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Narodowe Centrum Badan Jadrowych

Breast cancer metastatic

Not recruiting

Study of Nivolumab After Initial Treatment in Patients with Metastatic Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Breast cancer metastatic

Not recruiting

Study on Nivolumab and Cisplatin for Patients with Metastatic Triple Negative Breast Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Endometriosis

Not recruiting

Study on the Use of PET Scans with Fludeoxyglucose (18F) for Diagnosing Endometriosis in Patients with Symptoms

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Furosemide
  • Sponsor:Centre Hospitalier Universitaire De La Reunion

Hormone-refractory prostate cancer

Not recruiting

Study of Ipilimumab and Nivolumab for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Ipilimumab
  • Sponsor:Stichting Radboud University Medical Center

Triple negative breast cancer

Not recruiting

Study on the Effectiveness and Safety of Datopotamab Deruxtecan Compared to Chemotherapy in Adults with Advanced Triple-negative Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Breast cancer

Not recruiting

Study on Chemotherapy and Aromatase Inhibitors (Exemestane, Letrozole, Anastrozole) for Post-Menopausal Patients with Early Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:IRCCS Ospedale Policlinico San Martino

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

Penile cancer+2

Not recruiting

Study on the Use of Indocyanine Green and Technetium (99mTc) Nanocolloid for Sentinel Node Biopsy in Patients with Melanoma, Oral Cancer, or Penile Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Indocyanine Green
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Prostate cancer

Not recruiting

Study on Radiometabolic Therapy with 177Lu-PSMA for Patients with Advanced or Metastatic Tumors

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:177LU-PSMA-I&T
  • Sponsor:Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab77 clinical trialsLetrozole73 clinical trialsFulvestrant58 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane46 clinical trialsAnastrozole44 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.